Novavax (NVAX) News Today

Novavax, Inc. (NASDAQ: NVAX) shares are moving higher as investors react to a mix of strong earnings-related momentum, positive competitive commentary, and heavy trading activity.

• Positive Sentiment: Novavax’s first-quarter results beat expectations, helping fuel a sharp rerating in the stock as investors responded to better-than-expected revenue and earnings performance. Article Title
• Positive Sentiment: The company said patients were “twice as likely” to choose Novavax’s COVID shot over Moderna’s in a recent comparison, adding to optimism around its vaccine positioning. Article Title
• Positive Sentiment: Unusually large call-option buying suggests traders are positioning for further upside in Novavax (NVAX), with options volume far above normal.
• Neutral Sentiment: Novavax also announced it will participate in the BofA Securities 2026 Health Care Conference, which may give management another venue to update investors on strategy and partnerships. Article Title
• Neutral Sentiment: TD Cowen reiterated a $9 price target, which is supportive but not a major new catalyst. Article Title

Overall, NVAX is benefiting from post-earnings momentum, improved sentiment around its COVID vaccine franchise, and speculative trading interest. The main takeaway for investors is that the stock’s rise appears tied to stronger-than-expected results and renewed confidence in Novavax’s competitive and partnership prospects.